| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Nuvalent Inc. | Neladalkib (NVL-655) - (ALKAZAR) | ALK-positive NSCLC | Phase 3 | Enrollment Initiation | Oral | Oncology |
| Nuvation Bio Inc. Class A | IBTROZI (taletrectinib) - (TRUST-IV) | ROS1-Positive Early-Stage Non-Small Cell Lung Cancer | Phase 3 | Enrollment Initiation | Oral | Oncology |
| Nuvation Bio Inc. Class A | Safusidenib | High-Grade IDH1-Mutant Glioma | Phase 2 | Enrollment Initiation | oral | Oncology |
| Nuvation Bio Inc. Class A | Taletrectinib - (TRUST-I) (China) | ROS1-positive non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| ObsEva | Linzagolix (OBE2109) | Uterine fibroids | NDA Filing | Oral | Women's Health | |
| ObsEva | Linzagolix (OBE2109) - (PRIMROSE 1) | Uterine fibroids | NDA Filing | Oral | Women's Health | |
| ObsEva | Linzagolix (OBE2109) | Uterine fibroids | NDA Filing | Oral | Women's Health | |
| ObsEva | Linzagolix (OBE2109) - (PRIMROSE 1) | Uterine fibroids | NDA Filing | Oral | Women's Health |